1 / 23

Analysis of the Glucocerebrosidase (GBA) and GTP Cyclohydrolase-1 (GCH1) genes in a UK cohort of familial Parkinson’s Di

Analysis of the Glucocerebrosidase (GBA) and GTP Cyclohydrolase-1 (GCH1) genes in a UK cohort of familial Parkinson’s Disease patients. Piers Fulton, West Midlands Regional Genetics Laboratory Trainee Project 2009/2010. Parkinson’s Disease (PD).

decker
Download Presentation

Analysis of the Glucocerebrosidase (GBA) and GTP Cyclohydrolase-1 (GCH1) genes in a UK cohort of familial Parkinson’s Di

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Analysis of the Glucocerebrosidase (GBA) and GTP Cyclohydrolase-1 (GCH1) genes in a UK cohort of familial Parkinson’s Disease patients. Piers Fulton, West Midlands Regional Genetics Laboratory Trainee Project 2009/2010

  2. Parkinson’s Disease (PD) Progressive, incurable neurodegenerative disorder. Affects >1% of 55 year olds, >3% of over 75 year olds. Second most common neurodegenerative disorder after Alzheimer’s Disease. Clinical Symptoms: Bradykinesia – slowed movement. Rest tremor. Muscle rigidity. Dementia (20%), hallucinations, postural instability, ‘freezing’/motor blocks, dysautomnia, dystonic cramps.

  3. Pathology of Parkinson’s Disease Loss of dopaminergic cells in the substantia nigra. These cells have an important role in control of movement.

  4. Causes of PD Vast majority of cases: no strong family history or clear cause of PD (idiopathic). Multifactorial disease. Genetics and environmental risk factors (age, sex, pesticide exposure, head injury) play a role. Small proportion of cases (<5%): Mendelian inheritance pattern.

  5. Mendelian Causes of PD Genetests lists seven genes or mapped loci with an established link to AD or AR PD. Most relevant to this project: LRRK2. Mutations cause 2-7% of Autosomal Dominant familial PD. LRRK2 PD follows a similar disease course to idiopathic PD.

  6. This study • Test a UK-recruited cohort of familial Parkinson’s Disease patients for mutations in the PD candidate genes GBA and GCH1. • Identify any patients carrying mutations in LRRK2 and GBA/GCH1.

  7. Study Cohort • 46 UK-based familial PD patients recruited at the Queen Elizabeth Hospital, Birmingham. • All unrelated, each has at least 2 affected family members, apparent AD inheritance. • LRRK2 previously sequenced in all patients: 7 carriers of pathogenic mutations. • GCH1 previously sequenced in one patient: GCH1 point mutation identified. • Patient recruitment, LRRK2 and GCH1 sequencing: David Nicholl, Alistair Lewthwaite and colleagues.

  8. Glucocerebrosidase (GBA) 1q21 Essential for breakdown of glucosylceramide in lysosomes. Mutations in GBA may cause Gaucher disease. AR lysosomal storage disorder. Parkinsonism is a rare complication.

  9. Glucocerebrosidase (GBA) Previously reported association between GBA mutations, increased PD risk, lower age of PD onset in patients unaffected by Gaucher disease. Limited previous research into frequency of GBA mutations in familial PD. Nichols et al (2009): 12.8% of large US familial PD cohort carried one of five pathogenic GBA mutations, v. 5.3% of controls.

  10. Sequencing GBA Sequencing of all 11 exons + flanking regions of GBA. GBA has a 98% homologous pseudogene (GBAP) 16kb downstream, complicates primer design. ~10kb Long Range-PCR fragment amplified, nested PCR and sequencing of exons from diluted LR-PCR product. GBA locus should be amplified even if partly replaced with GBAP-derived sequence by homologous recombination/gene conversion (~12% of mutant alleles are recombinant).

  11. GBA sequencing results Complete sequence obtained for 45/46 patients. Five potentially pathogenic missense variants identified in five patients. Patient HGVS Severe (null): p.Arg159Trp, p.Gly234Glu. Medium/severe: p.Leu483Pro. Mild: p.Arg502Cys. Mild/polymorphism: p.Thr408Met. • p.Arg159Trp/N • p.Gly234Glu/N • 3 p.Arg502Cys/N • 4 p.Thr408Met/N • p.Leu483Pro/ • p.Thr408Met

  12. Is p.Thr408Met/N pathogenic? Patient 4: p.Thr408Met/N Also carries a LRRK2 frameshift mutation. Patient 5: p.Leu483Pro/p.Thr408Met p.Thr408Met is unlikely to be a major contributor to the PD phenotype. Inheritance pattern (AD) not consistent with inheritance of two disease-causing alleles. No family history of Gaucher disease in 5’s family. (Conclusion consistent with Eblan et al. 2006, Gan-Or et al. 2009).

  13. Do GBA mutations alter age of onset in fPD? 4/45 patients (8.9%) carry a pathogenic GBA mutation. Mean age of onset of GBA mutation carriers = 42.3 years (Range: 28-54) . Mean age of GBA mutation non-carriers = 59.4 years (Range: 30-78). P-value (T-test): p=0.0098. GBA mutation carriers have a significantly earlier age of onset than non-carriers.

  14. GTP Cyclohydrolase-1 (GCH1) 14q21.1-q22.2 Essential role in dopamine synthesis. Mutations in GCH1 can cause Dopa-Responsive Dystonia (DRD). AD neurological disorder, variable penetrance, usually childhood onset. Parkinsonism is a common symptom of DRD.

  15. Why test GCH1? Family investigated at Queen Elizabeth Hospital: Variable neurological phenotype: PD (2 patients) or DRD (two patients). Novel GCH1 missense mutation (p.Glu2Gly) identified in DRD and PD patients, not in unaffected family members. Conclusion: family carries a GCH1 mutation with variable phenotype. My project: screen GCH1 in fPD cohort, which includes the proband from the previously investigated family.

  16. Testing GCH1 • Sequencing • PCR, sequencing of all six coding exons and flanking regions. • 2. MLPA • P052-C1 Parkinson probemix, contains probes for 5 GCH1 exons (exon 4 not covered).

  17. Results • Sequencing • p.Glu2Gly confirmed in original proband. • No other known pathogenic mutations identified. • UV, p.Pro23Leu identified in patient 19. Also carries LRRK2 p.Gly2019Ser. • Same GCH1/LRRK2 genotype in patient 19’s affected sister.

  18. Results Is p.Pro23Leu pathogenic? Previously identified in DRD patients and controls: evidence suggests either a mild mutation or a polymorphism. Inheritance pattern (AD) not consistent with inheritance of two disease-causing alleles. Further work to assess co-segregation with disease in patient 19’s family is justified.

  19. Results 2. MLPA Poor quality results due to low DNA concentration and quality. No GCH1 deletions or duplications detected in 39/46 patients (7 patients failed).

  20. Conclusions GBA Pathogenic GBA mutations detected in 8.9% of a UK-recruited cohort of unrelated familial PD patients. GBA mutation carriers found to have a significantly lower age of PD onset than non-carriers. GBA mutations are a risk factor in familial PD in the UK population.

  21. Conclusions GCH1 No known pathogenic GCH1 mutations identified. One unclassified variant identified in a LRRK2 mutation carrier. GCH1 mutations are not a significant risk factor in fPD in the UK population.

  22. Conclusions Inheritance of mutations in multiple genes No conclusive evidence of an additive effect of multiple risk alleles. LRRK2 mutation/GBA UV and LRRK2 mutation/GCH1 UV combination each seen in 1 patient.

  23. Acknowledgements Queen Elizabeth Hospital, Birmingham: David Nicholl, Alistair Lewthwaite. West Midlands Regional Genetics Laboratory: Fiona Macdonald, Jennie Bell, Yvonne Wallis, Matthew Smith, Kirsten McKay, Hayley Simm and sequencing team.

More Related